Clinical Implementation of<sup>177</sup>Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges
Praful Ravi, Bridget Whelpley, Emma Kelly, Andrew Wolanski, Jolivette Ritzer, Matthew J. Robertson, Hina Shah, Alicia K. Morgans, Xiao X. Wei, Rajitha Sunkara, Mark M. Pomerantz, Mary‐Ellen Taplin, Kerry L. Kilbridge, Atish D. Choudhury, Heather A. Jacene
Abstract
In March 2022, 177Lu-PSMA-617 (177Lu-vipivotide tetraxetan) received Food and Drug Administration approval for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men with prostate-specific membrane antigen (PSMA)–avid disease who have received prior chemotherapy and a novel
Topics & Concepts
Prostate cancerFood and drug administrationMedicineGlutamate carboxypeptidase IIOncologyDiseaseInternal medicineCancerPharmacologyProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsPARP inhibition in cancer therapy